Data Collection
For each patient, demographic and laboratory data including past medical
and drug history, outcomes, baseline complete blood count and
inflammatory markers including C-reactive protein (CRP), erythrocyte
sedimentation rate (ESR), ferritin and lactate dehydrogenase (LDH), and
liver function tests were recorded. Also, vital signs on admission and
selected pharmacotherapy for management of COVID-19 besides, the
administration of atorvastatin and other cardiovascular medications
including Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin
Receptor Blockers (ARBs), and beta-blockers, were documented.
Atorvastatin use was defined as the administration of the medication on
1st day of admission.